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Near  infrared  spectroscopy  (NIRS)  methods  were  developed  for  the determination  of analytical  content
of an  antimalarial-antibiotic  (artesunate  and  azithromycin)  co-formulation  in hard  gelatin  capsule  (HGC).
The NIRS  consists  of  pre-processing  treatment  of  spectra  (raw  spectra  and  ﬁrst-derivation  of  two  spec-
tral zones),  a unique  principal  component  analysis  model  to ensure  the  speciﬁcity  and  then  two  partial






The  NIRS  methods  were  developed  and validated  with  no  reference  method,  since  the manufacturing
process  of  HGC  is basically  mixed  excipients  with  active  pharmaceutical  ingredients.  The  accuracy  pro-
ﬁles  showed  -expectation  tolerance  limits  within  the  acceptance  limits  (±5%).  The  analytical  control
approach  performed  by reversed  phase  (HPLC)  required  two different  methods  involving  two  different
preparation  and  chromatographic  methods.  NIRS  offers  advantages  in  terms  of  lower  costs  of  equipment
and procedures,  time  saving,  environmentally  friendly.. Introduction
Malaria manifests itself most commonly with fever and other
igns and symptoms that are aspeciﬁc and can be caused by other
nfections [1].  Differential diagnosis may  be very difﬁcult, even
hen the IMCI (Integrated Management of Childhood Illnesses)
uidelines and algorithms are applied [2].  The diagnosis of malaria
equires that parasites are observed microscopically or parasite
ntigens are detected by means of rapid diagnostic tests. However,
uch tests may  not be available in rural communities (where the
ajority of cases occurs), and in malaria-endemic areas sometimes
ven the detection of malaria parasites cannot rule out other infec-
ions. Microbiological and clinical diagnosis of bacterial infections
s challenging in rural tropics.
Both malaria and bacterial pneumonia and sepsis can progress
apidly if not promptly diagnosed and treated. Children become
nable to take medications orally (because of intense vomiting), but
njections are generally not available in rural communities or even
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sometimes in peripheral health facilities (nor are they advisable if
safe injections cannot be guaranteed).
Rectal artesunate (AS) prevents malaria progression and reduces
malaria mortality [3] when given to children who cannot take
oral medications (a condition referred to “moderately severe”,
or “non-per-os” malaria) who are further referred to the near-
est health facility where appropriate follow-on treatment can be
instituted. Similarly, combining AS with an antibiotic would cover
both malaria and bacterial infections; if this antibiotic had, like
azithromycin (AZ) does, also antimalarial properties [4–7], addi-
tional antimalarial effects and protection against resistance would
be conferred.
Therefore, we  have studied the possibility of developing a rectal,
ﬁxed-dose combination of AS plus AZ, as an emergency pre-referral
treatment of children living in malaria endemic areas who develop
fever and deteriorating conditions and cannot thus be treated
orally.
The selected rectal form is Hard Gelatin Capsules (HGC) con-
Open access under CC BY license.taining both Active Pharmaceutical Ingredients (APIs) as powder
mixture with excipients. As part of this development, we were faced
with the challenge of developing a single method for API content
determination for quality control.


























































Azithromycin/Artesunate formulation composition in HGC.
Composition HGC content
mg  per HGC %w/w
Azithromycin, 2H2O 419 51.06
Artesunate 300 36.56C. Boyer et al. / Journal of Pharmaceutica
A single chromatographic method using RP-HPLC with grafted
ilica is not feasible because of the eluotropic strength and the pH of
he mobile phase. We  therefore considered a method by high tem-
erature liquid chromatography using non-aqueous mobile phase
nd porous graphitic carbon as stationary phase hyphenated with
vaporative light scattering detection (ELSD) [8] for the elution in
he same run of the both AS and AZ. However this method is not
ufﬁciently robust for analytical control purpose due to the poor
hermostability of AS associated with less reproducibility of ELSD
han UV spectroscopy. However, the quality control of AS and AZ in
GC by RP-HPLC with UV detection required two  different meth-
ds, and thus two chromatographic equipments to perform the
etermination content of the two APIs. As HPLC is time-consuming,
xpensive, labor-intensive and requires solvents, there is a need for
 fast, accurate and economical methods for AS and AZ quantiﬁca-
ion in the HGC.
Near infrared spectroscopy (NIRS) is attractive because it is rapid
direct recording of spectra with little or no sample pre-treatment),
roduces no chemical waste, and provides chemical and physical
nformation about samples. NIRS is used as a quality control tech-
ique in the pharmaceutical industry and represents a useful tool
or direct analysis of pharmaceutical samples [9–11].
At the same time, the combination of a chemometric software
nd the use of multicomponent analytical methods are required
o interpret the large amount of information present in NIR spec-
ra. Partial Least Squares (PLS) is a regression method frequently
sed for quantitative purposes in which the calibration involves
orrelating the data in the spectral matrix X with the data in the
oncentration matrix Y. PLS needs (i) a calibration set whereby the
elationship between the spectra and the concentration of the API
s derived, followed by (ii) a validation set for the determination of
he API concentration from the spectra of the analyzed samples set
ccording to the calibration results.
The presence of AS and AZ in high concentrations in the formu-
ated product (51.06 and 36.56%, w/w, respectively) compensates
or the limited sensitivity of the NIRS technique. Feasibility studies
f using NIRS to identify counterfeit drugs containing AS have been
eported [12,13] but AS lacks functions suitable for quantitative
valuation. Gabriëls [14] reported a CZE-technique for the separa-
ion of artesunate and artelinic acid using micellar electrokinetic
apillary electrophoresis with UV-detection at 185 nm. Green [15]
valuated a technique combining refractometry and colorimetry as
imple and accurate ﬁeld assays for rapid assessment of the content
f AS tablets. As for AZ, a NIRS identiﬁcation system has been devel-
ped for the analysis of AZ tablets from different manufacturers
16].
The objective of this work was to investigate the suitability of the
IRS technique associated with chemometrics for quantiﬁcation of
S and AZ in HGC in order to avoid the use of two different HPLC
ethods. One model for each API was developed, and the analyti-
al methods were validated. The development of the methods was
ttempted without a reference [17,18] and compared to validation
esults obtained by HPLC.
. Material and methods
.1. Chemicals and reagents
AS was a generous gift of DNDi (Drug for Neglected Dis-
ase initiative, Geneva, Switzerland) purchased from Knoll BASF
harma (Liestal, Switzerland). -Dihydroartemisinin (DHA, AS
ain metabolite) was synthesized from COMIPSO (Bordeaux,
rance). AZ was purchased from Pﬁzer (USA). Microcrystalline cel-
ulose (Emcocell 90, Mendell, Finland) and colloidal silica (Aerosil
00, COOPER, France) were of pharmaceutical grade.Microcrystalline cellulose 100 12.18
Colloidal silica 1.638 0.20
2.2. FT-NIRS equipment and recording of NIR spectra
Spectra were acquired on a Thermo Scientiﬁc FT-NIR analyser
model Antaris II (ThermoScientiﬁc Instrument, Madison, USA) con-
trolled by Result and Omnic softwares. This instrument is equipped
with a Michelson interferometer, a matched InGaAs detector, a
quartz halogen light source (50 W)  and an Antaris II Integrating
sphere for measuring solids by diffuse reﬂectance.
The spectrophotometer was equipped with the software pack-
age from ThermoScientiﬁc Instrument, including OMNIC version
6.1a for spectral acquisition and TQ Analyst version 6.21 for spectral
processing and chemometric analysis. All measurements of pow-
der mixtures were collected in the diffuse reﬂectance mode and
spectra were converted in absorbance units. Each powder blend
was  poured in a 1.5 mL  glass vial (Chromacol – 10 mm in diame-
ter – from ThermoScientiﬁc Instrument Inc.), put on the sampling
sapphire window of the reﬂectance module and scanned directly
through the bottom of the vial (a special holder made to ﬁt the shape
of the vial kept the container in centered position over the window).
Each spectrum was  the average of 32 co-added scans, obtained with
usual resolution of 8 cm−1 over the range of 4000–9999 cm−1 and
corrected against the background spectrum of room environment
which was  performed routinely. Each sample was  recorded in trip-
licate with turnover between successive recordings to obtain an
average spectrum.
2.3. HGC manufacturing
All components of HGC (Table 1) were mixed in a planetary
mixer for 15 min. The powder blend was ﬁlled into colorless 000
HGC with semi-automatic capsule ﬁller equipped with vibrator
(LGA QB 30, Laboratoire des Gélules et des Azymes, France). The
formulation was  optimized for its ﬂowing properties. A batch of
1200 HCGs was prepared and tested according to Pharmacopoeia
standards.
2.4. Development and validation of NIRS model
A Partial Least Squares (PLS) model as provided in the TQ Analyst
software was used for the quantiﬁcation of AS and AZ with two
different calibration models.
All data were mean centered before analysis. Spectral pre-
treatments tested to construct the calibration models include
Standard Normal Variate (SNV) and ﬁrst Stavisky–Golay derivative
with 11-points moving window and ﬁtting to a second-order poly-
nomial. PLS calibration models were constructed and the goodness
of ﬁt of the models was  assessed in terms of their standard rela-
tive errors, i.e. the Root Mean Square Error of Calibration (RMSEC),
and Root Mean Square Error of Prediction (RMSEP). The optimum
number of PLS factors used to construct the models was the one
resulting in the lowest error of prediction for an external set of val-
idation samples, i.e. the Root Mean Square Error Cross Validation
(RMSECV). The predictive ability of the model was tested by apply-
ing the validation set that was not used during its development.
For the NIRS calibration method development, for each API,
four sets of reconstituted powder blends were performed at API
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Table  2
Weight of the different HGC components for the AZ calibration and validation models (AS ﬁxed).
% Calibration set Validation set
AS (mg) AZ (mg) Placeboa (mg) Total (mg) AS (mg) AZ (mg) Placebob (mg) Total (mg)
80 836.6 750.0 465.2 2051.8 418.6 375.5 232.4 1026.5
85  889.1 749.6 413.5 2052.2 445.5 375.2 205.8 1026.4
90  942.5 750.6 360.6 2053.7 471.5 375.4 180.2 1027.1
95 993.5  750.5 308.2 2052.2 496.2 375.3 154.5 1026.0
100 1046.5  750.3 256.3 2053.1 523.4 374.9 128.1 1026.4
105  1099.5 750.1 203.4 2053.0 549.2 375.6 101.6 1026.4
110  1150.8 750.2 151.4 2052.4 577.8 375.4 76.1 1029.3
115  1206.4 750.1 98.8 2055.3 602.9 375.6 49.6 1028.1
120  1256.6 750.2 46.5 2053.3 628.3 375.3 23.6 1027.2
a qsp 2053.64 mg.
b qsp 1026.82 mg.
Table 3
Weight of the different HGC components for the AS calibration and validation models (AZ ﬁxed).
% Calibration set Validation set
AS (mg) AZ (mg) Placeboa (mg) Total (mg) AS (mg) AZ (mg) Placebob (mg) Total (mg)
80 602.1 1046.5 405.0 2053.6 301.8 535.5 202.9 1040.2
85  637.5 1046.1 368.1 2051.7 319.6 524.1 184.4 1028.1
90  675.6 1047 330.7 2053.3 338.0 523.4 165.5 1026.9
95  712.6 1046.1 293.7 2052.4 356.8 523.0 146.2 1026.0
100  749.9 1045.0 256.4 2051.3 375.6 523.8 127.7 1027.1
105 787.8  1047.3 217.6 2052.7 395.4 522.9 109.2 1027.5
110  824.6 1045.9 181.0 2051.5 412.6 523.1 90.8 1026.5
115 862.3  1047.7 143.5 2053.5 431.9 523.3 71.1 1026.3
120  900.1 1045.5 105.9 2051.5 450.3 523.2 53.5 1027.0




























db qsp 1026.82 mg.
oncentrations ranging from 80 to 120% of the labeled concentra-
ion of the API of interest in HGC (the concentration of the other
PI is ﬁxed at 100%). Sets of calibration and validation for the mod-
ls development were performed as described in Tables 2 and 3,
or AZ and AS, respectively. Before weighing, the required compo-
ent was individually sieved to obtain a granulation under 250 m
ike in the HGC formulation process. 2053.6 mg and 1026.82 mg
f each blend were prepared for the calibration and validation
ets, respectively. The resulting mixtures were poured in test
ubes without grinding and serially mixed with manual turbula
uring 1 minute in order to ensure the homogeneity of the mate-
ial. Then each powder blend was aliquoted in 1.5 mL  glass vials
o reach 5 mm height of powder which corresponded to around
00 mg  of the mixtures. 6 and 3 vials for each concentration
evel were used for calibration and validation model development,
espectively.
.5. Validation of NIRS methods
For the speciﬁcity study of the NIRS methods, excipients mix-
ure (placebo) was prepared by weighting and mixing together
998.9 mg  of microcrystalline cellulose and 122.7 mg  of colloidal
ilica.
A mixture labeled “10% DHA” consists of 261.88 mg  of AZ,
68.75 mg  of AS, 18.75 mg  of DHA, 64.04 mg  of excipients mixture
i.e. placebo).
For the validation of the NIRS analytical methods, a new set of
amples for each API was prepared as previously described, with
ne API content varying while keeping the other one ﬁxed (and vice
ersa). Each set was composed of three levels (80, 100 and 120%) of
he API labeled concentration, and three independent replicates of
his set of samples were prepared and analyzed on three different
ays by two different persons to establish accuracy proﬁles.2.6. HPLC equipment and procedures
The HPLC system was  a Hewlett Packard HPLC 1050 series con-
sisting of a quaternary pump, a DAD detector, an online degasser,
an Agilent Chemstation LC 3D, a Rheodyne 7125 injection valve
(Cotati, California, USA) with injection volume at 5 L.
The HPLC method for AS determination [19] consisted of a
column X-Terra RP C18 (50 mm × 3 mm i.d., 3.5 m particle size)
Waters (Milford, MA,  USA) used with CH3CN–HCOOH (pH 2.85;
0.01 M)  (40:60, v/v) as mobile phase, thermostated at 60 ◦C and
ﬂow rate at 0.7 mL  min−1. The detection was  set at 220 nm. The
HPLC method for AZ determination [20] consists of a column Luna
C8 EC 5 m,  150 mm × 4.6 mm (Phenomenex, France) used with
CH3OH–phosphate buffer (pH 7.5; 30 mM)  (80:20, v/v) (swpH = 10)
as mobile phase, thermostated at 20 ◦C and ﬂow rate at 1 mL min−1.
The detection was set at 210 nm.
For sample preparation for HPLC, twenty capsules were milled.
Then 274 mg  and 196 mg  of this blend for AS and AZ content
measurements, respectively, were weighted, dissolved in 20 mL-
volumetric ﬂask with methanol, ﬁltrated with 0.45 m-ﬁlter and
ﬁnally diluted 10-fold in respective mobile phase.
2.7. HPLC validation methods
For the validation of the HPLC method procedure, two sets of
three levels (80, 100 and 120%) of the API labeled concentration
were prepared, one composed only with API and the other com-
posed by samples of reconstituted forms.
For the reconstituted form of 100% level of AS HPLC procedures,
100 mg  of AS with 139.7 mg  of AZ and 34.1 mg  of the placebo were
weighted, dissolved in 20 mL-volumetric ﬂask with methanol, ﬁl-
trated with 0.45 m-ﬁlter and ﬁnally diluted 10-fold in mobile
phase. Then only the weight of AS varied for 80 and 120% levels at
C. Boyer et al. / Journal of Pharmaceutical and Biomedical Analysis 67– 68 (2012) 10– 15 13









































Results of PLS models for AZ and AS.
AZ AS
Number of factor 5 6
r  0.999 0.999Fig. 1. Spectra of pure compounds AS a
0 and 120 mg,  respectively. For each of the three levels of reconsti-
uted form and API sets, 5 and 3 different solutions were prepared,
espectively.
For the reconstituted form of 100% level of AZ HPLC procedures,
00 mg  of AZ with 71.6 mg  of AS and 24.4 mg  of the placebo were
eighted, dissolved in 20 mL-volumetric ﬂask with methanol, ﬁl-
rated with 0.45 m-ﬁlter and ﬁnally diluted 10 fold in mobile
hase. Then only the weight of AZ varied for 80 and 120% levels at
0 and 120 mg,  respectively. For each of the three levels of reconsti-
uted form and API sets, 5 and 3 different solutions were prepared,
espectively.
. Results and discussion
.1. Calibration models development
For method development in NIRS without a reference method,
he parameters of the pharmaceutical process must be taken into
ccount. Granulation and milling for the HGC formulation may
ffect NIR spectra. Reliable dosage requires a uniform distribution
f the API and the excipients in the pharmaceutical blend; only
he ﬁrst 0.75 mm  layer of a powder blend is analyzed with diffuse
eﬂectance spectroscopy and the analysis depends on particle size
21]. In order to obtain the most representative spectrum from each
ample, the individual component powders were granulated with a
imilar particle size (∼250 m)  as in the formulation process. After
ixing, identical amounts of the blend were poured in vials before
cquisition of the spectra, which led to equivalent powder height
or NIRS light path (∼5 mm).  For each concentration, three spec-
ra obtained after successive turnarounds were averaged to give a
ean spectrum for each sample. The time of manual turbula mixing
as increased to 1 min, as the time at which the mixture became
niform with consistent spectra obtained from different vials.
The spectrum of an HGC sample is dominated by the AZ spec-
ral features (Fig. 1). AZ represents 51.06% (w/w) in the capsule
nd its spectrum shows distinct spectral differences from that of
lacebo. So the PLS regression which can correlate NIRS data with
PI concentrations was  applied in spectral ranges which involved
he largest differences between placebo and HGC spectra, i.e. two
egions ranging from 5311 to 6811 and from 7200 to 9999 cm−1.
The development of a NIRS model consists in checking different
pectral pre-treatments as well as its combination with different
pectral ranges. Among the most widely used pre-processing tech-
iques, SNV [22] reduces physical variability, adjusts for baseline
hifts between samples, minimizes the spectral contribution of dif-
erences in particle size and does not increase noise in the signalError [−2.3; 2.9] [−2.5; 2.6]
RMSEC 0.55 0.38
RMSEP 1.34 1.31
[23]. As for ﬁrst or second spectral derivative, these treatments
can remove both additive and multiplicative effects in the spectra,
thus reducing spectral contributions from the physical properties
of samples. All these pre-processing approaches were tested with a
view to constructing the calibration models. At the end of this pro-
cess, the combination of SNV pre-treatment associated with the
ﬁrst derivative transformed spectra and the raw spectra over the
respective spectral range 5311–6811 and 7200–9999 cm−1 was  the
one providing the best results in all instances.
In order to allow for independence between respective API
concentrations, two  different models were created for AS and AZ
quantiﬁcation, respectively. For each model, calibration and vali-
dation sets consisted of 6 and 3 individual mixtures, respectively,
at each level. As the sets contained nine levels, the calibration and
validation sets consisted respectively of 54 and 27 samples.
The external validation of the method was performed with the
samples of the validation set, i.e. samples that are independent from
those used to calibrate the method. It was done in parallel with the
threshold setting, to ensure a correct selection of this parameter.
Once the calibration models were deﬁned, their predictive ability
was  tested using the validation set. The calibration models were
chosen in terms of predictive ability and prediction errors (Table 4).
The selected strategies allowed models to be constructed from a
number of PLS signiﬁcant factors, i.e. 5 and 6 for AZ and AS, respec-
tively. The determination coefﬁcient values were close to 1 for each
model. RMSEP and RMSEC values were weak, with RMSEC smaller
than RMSEP. These models displayed excellent results in terms of
merit values at the calibration and validation stages. Each interval
error never exceeded the acceptance threshold. So the PLS method
was  validated before its application for quantitative determination
of AZ and AS in different HGC samples.
3.2. ValidationThe validation of the NIRS measurements associated with mul-
tivariate analyses was considered to fulﬁll the expectations of ICH
Q2 (R1) guideline on validation of analytical procedures [24].
14 C. Boyer et al. / Journal of Pharmaceutical and Biomedical Analysis 67– 68 (2012) 10– 15
F 00–9999 cm−1). Spectra were treated with combination of SNV pre-treatment associated



































Hig. 2. Scores plot resulting from a PCA of the API speciﬁc region (5311–6811 and 72
ith  the ﬁrst derivative transformed spectra and the raw spectra, respectively of ea
.2.1. Speciﬁcity
For NIRS methods, applying the PLS model is not enough per se
o ensure method speciﬁcity. To test the speciﬁcity of the meth-
ds for APIs quantiﬁcation, potential challenges are presented to
he library. The speciﬁcity proof-set included placebos, degrada-
ion product (i.e. DHA) of AS, HGC formulations from the laboratory
harmaceutical production. Degradation of AS occurred by inter-
ction with excipients, other APIs or humidity [25]. The library
ejected all the samples from the speciﬁcity proof-set, which was
aken as evidence of its speciﬁcity. Fig. 2 presents a scores plot from
 PCA where the speciﬁcity proof-set was included. In this plot, the
istance of the different products from the HGC samples shows that
his identiﬁcation method clearly discriminates different products.
.2.2. Accuracy proﬁles
The validation of the analytical methods was  done using the
ccuracy proﬁles approach [26–31].  The accuracy of an analytical
rocedure expresses the agreement between the experimental and
he conventional true value or an accepted reference value. Accu-
acy represents the sum of systematic (trueness) and random errors
precision) and therefore, expresses the inherent total error of the
esult. For a pharmaceutical formulation, acceptable limits were
xed at ±5%. As shown in Figs. 3 and 4, -expectation tolerance
imits obtained with NIRS approaches were within in these limits.
.3. Comparison between NIRS and HPLC methods
HPLC required two independent methods for determination of
he content of each API. The whole analytical procedures in terms
f sample preparation and chromatographic conditions were dif-
erent. The NIRS approach required the record of a single spectrum
hich required only the opening of the HGC. Then APIs content
etermination by NIRS was performed using one mathematical
odel for each API.
The NIRS and HPLC methods were validated within the ±5%
cceptance limits (Figs. 3 and 4). The validation performance
btained for each API was equivalent between NIRS and HPLC. How-
ver, with HPLC, the accuracy proﬁles of both APIs were obtained
ithin the ±5% acceptance limits with regression model between
he response R and the concentration C following linear relationship
 = aC + b where a and b are constant values. Therefore the use of the
PLC methods for analytical control purpose required additionalFig. 3. Accuracy proﬁles from the validation of HPLC (a) and NIRS (b) methods for
AS  determination content. Acceptance limits at ±5%.
concentration calibration before daily content determination. In
case of NIRS methods, as one PLS model was validated for each API,
no further analysis was required for the content determination of
APIs in the HGC.
Each HPLC method had a run time of 3 and 9 min  for AS and
AZ, respectively. It should also be noted that analyzing AS by HPLC
required extemporaneous sample preparation to ensure AS stabil-
ity. Further, RP-HPLC approaches were time-consuming, required
extensive sample preparation and consumed large quantities of sol-
vent especially in the case of AZ where the mobile phase required
80% of organic solvent.
The AS and AZ content measurements by the two different
instruments were performed on a fresh batch. The results obtained
from 6 determinations were 103.3% (RSD 2.6%) and 104.9% (RSD
3.5%) for AS, and 102.1% (RSD 1.7%) and 103.9% (RSD 4.4%) for AZ,
with NIRS and HPLC methods, respectively. Similar results were
thus obtained with an additional advantage of the NIRS instrument










































[ig. 4. Accuracy proﬁles from the validation of HPLC (a) and NIRS (b) methods for
Z  determination content. Acceptance limits at ±5%.
hich is less expensive to purchase and operate than a standard
PLC system.
. Conclusion
The proposed NIRS methods were validated for the determina-
ion of content of two APIs (AS and AZ) in the same pharmaceutical
orm. As the form is HGC, the pharmaceutical process was  very
imple and allows developing a chemometric model with no refer-
nce method, making also both the entire analytical development
nd sample preparation procedure environmentally friendly. In
ddition, using this approach instead of HPLC, circumvented the
roblem of API stability during sample preparation especially for
S, saved time, reduced considerably workload, minimized the
onsumption of disposable material and was thus economically
ompetitive.
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